Eloralintide, a selective, long‐acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept

Documenti analoghi

• A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
  di: Filip K. Knop, et al.
  Pubblicazione: (2024)
• Prevalence of complications and co‐morbidities in males and females with obesity: Real‐world insights from claims data analysis
  di: Jay P. Bae, et al.
  Pubblicazione: (2024)
• The role of incretin receptor agonists in the treatment of obesity
  di: Thomas Forst, et al.
  Pubblicazione: (2024)
• Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes
  di: Julio Rosenstock, et al.
  Pubblicazione: (2025)
• GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
  di: Tommaso Bucci, et al.
  Pubblicazione: (2025)